A high content clonogenic survival drug screening identifies maytansine as a potent radiosensitizer for meningiomas
This study highlighted the potential of maytansine as a potent inhibitor and radiosensitizer for meningiomas by inducing G2/M phase cell cycle arrest and enhancing DNA double-strand break damage. These findings opened up a promising path in the development of radiosensitizers aimed at treating this condition.
Authors
- Lingyang Hua (ORCID: https://orcid.org/0000-0002-1003-9289)
- Chunlin Shao (ORCID: https://orcid.org/0000-0001-9336-9912)
- Ye Gong (ORCID: https://orcid.org/0000-0001-5647-3008)
- Leihao Ren
- Jinxiu Yu (ORCID: https://orcid.org/0000-0001-5316-8585)
- Jiaojiao Deng (ORCID: https://orcid.org/0000-0002-6549-9688)
- Tianqi Wu
- Yi Hui
Institutions
- Shanghai Medical College of Fudan University (CN)
- Fudan University (CN)
- Shanghai East Hospital (CN)
- Huashan Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-18
- DOI
- https://doi.org/10.3389/fimmu.2025.1557165
- Citations
- 1
- Primary Topic
- Meningioma and schwannoma management
- Type
- article
- Field-Weighted Citation Impact
- 1.35